Department of Physiology, Faculty of Medicine, Université de Montréal, C,P, 6128, Succursale Downtown, Montréal, Québec, H3C 3J7, Canada.
J Neuroinflammation. 2010 Jun 29;7(1):36. doi: 10.1186/1742-2094-7-36.
The pro-nociceptive kinin B1 receptor (B1R) is upregulated on sensory C-fibres, astrocytes and microglia in the spinal cord of streptozotocin (STZ)-diabetic rat. This study aims at defining the role of microglial kinin B1R in diabetic pain neuropathy.
Sprague-Dawley rats were made diabetic with STZ (65 mg/kg, i.p.), and 4 days later, two specific inhibitors of microglial cells (fluorocitrate, 1 nmol, i.t.; minocycline, 10 mg/kg, i.p.) were administered to assess the impact on thermal hyperalgesia, allodynia and mRNA expression (qRT-PCR) of B1R and pro-inflammatory markers. Spinal B1R binding sites ((125I)-HPP-desArg10-Hoe 140) were also measured by quantitative autoradiography. Inhibition of microglia was confirmed by confocal microscopy with the specific marker Iba-1. Effects of intrathecal and/or systemic administration of B1R agonist (des-Arg9-BK) and antagonists (SSR240612 and R-715) were measured on neuropathic pain manifestations.
STZ-diabetic rats displayed significant tactile and cold allodynia compared with control rats. Intrathecal or peripheral blockade of B1R or inhibition of microglia reversed time-dependently tactile and cold allodynia in diabetic rats without affecting basal values in control rats. Microglia inhibition also abolished thermal hyperalgesia and the enhanced allodynia induced by intrathecal des-Arg9-BK without affecting hyperglycemia in STZ rats. The enhanced mRNA expression (B1R, IL-1beta, TNF-alpha, TRPV1) and Iba-1 immunoreactivity in the STZ spinal cord were normalized by fluorocitrate or minocycline, yet B1R binding sites were reduced by 38%.
The upregulation of kinin B1R in spinal dorsal horn microglia by pro-inflammatory cytokines is proposed as a crucial mechanism in early pain neuropathy in STZ-diabetic rats.
在链脲佐菌素(STZ)糖尿病大鼠的脊髓中,伤害感受性激肽 B1 受体(B1R)在感觉 C 纤维、星形胶质细胞和小胶质细胞上上调。本研究旨在确定小胶质细胞激肽 B1R 在糖尿病痛性神经病中的作用。
用 STZ(65mg/kg,ip)使 Sprague-Dawley 大鼠产生糖尿病,4 天后,给予两种小胶质细胞特异性抑制剂(氟柠檬酸,1nmol,it;米诺环素,10mg/kg,ip),以评估其对热痛觉过敏、触觉过敏和 B1R 及促炎标志物的 mRNA 表达的影响。还通过定量放射自显影术测量脊髓 B1R 结合位点((125I)-HPP-desArg10-Hoe 140)。通过特异性标志物 Iba-1 用共聚焦显微镜确认小胶质细胞的抑制作用。通过鞘内和/或全身给予 B1R 激动剂(des-Arg9-BK)和拮抗剂(SSR240612 和 R-715)来测量对神经病理性疼痛表现的影响。
与对照组大鼠相比,STZ 糖尿病大鼠表现出明显的触觉和冷触觉过敏。鞘内或外周阻断 B1R 或抑制小胶质细胞可使糖尿病大鼠的触觉和冷触觉过敏时间依赖性逆转,而不影响对照组大鼠的基础值。小胶质细胞抑制也消除了鞘内 des-Arg9-BK 诱导的热痛觉过敏和增强的触觉过敏,而不影响 STZ 大鼠的高血糖。STZ 脊髓中 B1R、IL-1β、TNF-α和 TRPV1 的 mRNA 表达(B1R、IL-1β、TNF-α、TRPV1)和 Iba-1 免疫反应性增强被氟柠檬酸或米诺环素正常化,但 B1R 结合位点减少 38%。
促炎细胞因子在脊髓背角小胶质细胞中上调激肽 B1R 被提议作为 STZ 糖尿病大鼠早期痛性神经病的关键机制。